Minchul Kim

Minchul Kim

Auto-generated profile, based on publicly available information

Minchul Kim

Laboratory of Syncytial Cell Biology, IGBMC, Institute of Genetics and of Molecular and Cellular Biology, 67400 Illkirch, France

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Cell Reports
Verified
Journal Article
Open access
MKMinchul Kim
Minchul Kim
TKTaekhoon Kim
Taekhoon Kim
RJRandy L. Johnson
Randy L. Johnson
DLDae-Sik Lim
Dae-Sik Lim
YAP (yes-associated protein) and TAZ are oncogenic transcriptional co-activators downstream of the Hippo tumor-suppressor pathway. However, whether YAP and/or TAZ (YAP/TAZ) engage in transcriptional co-repression remains relatively unexplored. Here, we directly demonstrated that YAP/TAZ represses numerous target genes, including tumor-suppressor genes such as DDIT4 (DNA-damage-inducible transcript 4) and Trail (TNF-related apoptosis-inducing ligand). Mechanistically, the repressor function of YAP/TAZ requires TEAD (TEA domain) transcription factors. A YAP/TAZ-TEAD complex recruits the NuRD complex to deacetylate histones and alters nucleosome occupancy at target genes. Functionally, repression of DDIT4 and Trail by YAP/TAZ is required for mTORC1 (mechanistic target of rapamycin complex 1) activation and cell survival, respectively. Our demonstration of the transcriptional co-repressor activity of YAP/TAZ opens a new avenue for understanding the Hippo signaling pathway.

3 May 2013 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
MKMinchul Kim
Minchul Kim
MKMiju Kim
Miju Kim
SLSeunghee Lee
Seunghee Lee
SKShinji Kuninaka
Shinji Kuninaka
Hideyuki SayaHideyuki Saya
Hideyuki Saya
DLDae‐Sik Lim
Dae‐Sik Lim
Actin cytoskeletal damage induces inactivation of the oncoprotein YAP (Yes‐associated protein). It is known that the serine/threonine kinase LATS (large tumour suppressor) inactivates YAP by phosphorylating its Ser127 and Ser381 residues. However, the events downstream of actin cytoskeletal changes that are involved in the regulation of the LATS–YAP pathway and the mechanism by which LATS differentially phosphorylates YAP on Ser127 and Ser381 in vivo have remained elusive. Here, we show that cyclic AMP (cAMP)‐dependent protein kinase (PKA) phosphorylates LATS and thereby enhances its activity sufficiently to phosphorylate YAP on Ser381. We also found that PKA activity is involved in all contexts previously reported to trigger the LATS–YAP pathway, including actin cytoskeletal damage, G‐protein‐coupled receptor activation, and engagement of the Hippo pathway. Inhibition of PKA and overexpression of YAP cooperate to transform normal cells and amplify neural progenitor pools in developing chick embryos. We also implicate neurofibromin 2 as an AKAP (A‐kinase‐anchoring protein) scaffold protein that facilitates the function of the cAMP/PKA–LATS–YAP pathway. Our study thus incorporates PKA as novel component of the Hippo pathway.

1 February 2017 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
HKHan-Byul Kim
Han-Byul Kim
MKMinchul Kim
Minchul Kim
YPYoung-Soo Park
Young-Soo Park
IPIntae Park
Intae Park
TKTackhoon Kim
Tackhoon Kim
SMSeung Jae Myung
Seung Jae Myung

23 November 2015 in EMBO Reports
Verified
Journal Article
Open access
PDF file
MKMiju Kim
Miju Kim
MKMinchul Kim
Minchul Kim
SPSeong‐Jun Park
Seong‐Jun Park
CLCheolju Lee
Cheolju Lee
DLDae‐Sik Lim
Dae‐Sik Lim
LATS1/2 (large tumor suppressor) kinases and the Angiomotin family proteins are potent inhibitors of the YAP (yes‐associated protein) oncoprotein, but the underlying molecular mechanism is not fully understood. Here, we report for the first time that USP9X is a deubiquitinase of Angiomotin‐like 2 (AMOTL2) and that AMOTL2 mono‐ubiquitination is required for YAP inhibition. USP9X knockdown increased the LATS‐mediated phosphorylation of YAP and decreased the transcriptional output of YAP. Conversely, over‐expression of USP9X reactivated YAP in densely cultured cells. Both genetic and biochemical approaches identified AMOTL2 as a target of USP9X. AMOTL2 was found to be ubiquitinated at K347 and K408, which both reside in the protein's coiled‐coil domain. The AMOTL2 K347/408R mutant, which cannot be ubiquitinated, was impaired in its ability to inhibit YAP. Furthermore, ubiquitinated AMOTL2 can bind to the UBA domain of LATS kinase, and this domain is required for the function of LATS. Our results provide novel insights into the activation mechanisms of core Hippo pathway components.

1 September 2016 in Cell Reports
Verified
Journal Article
Open access
MKMinchul Kim
Minchul Kim
FLFalong Lu
Falong Lu
YZYi Zhang
Yi Zhang
ARID1A is frequently mutated in ovarian clear cell carcinoma (OCCC) and often co-exists with activating mutations of PIK3CA. Although induction of pro-inflammatory cytokines has been observed in this cancer, the mechanism by which the two mutations synergistically activate cytokine genes remains elusive. Here, we established an in vitro model of OCCC by introducing ARID1A knockdown and mutant PIK3CA into a normal human ovarian epithelial cell line, resulting in cell transformation and cytokine gene induction. We demonstrate that loss of ARID1A impairs the recruitment of the Sin3A-HDAC complex, while the PIK3CA mutation releases RelA from IκB, leading to cytokine gene activation. We show that an NF-κB inhibitor partly attenuates the proliferation of OCCC and improves the efficacy of carboplatin both in cell culture and in a mouse model. Our study thus reveals the mechanistic link between ARID1A/PIK3CA mutations and cytokine gene induction in OCCC and suggests that NF-κB inhibition could be a potential therapeutic option.

1 May 2018 in Genes & Development
Verified
Journal Article
Open access
PDF file
MKMinchul Kim
Minchul Kim
HWHagen Wende
Hagen Wende
JWJan Walcher
Jan Walcher
JKJohannes Kühnemund
Johannes Kühnemund
CCCyril Cheret
Cyril Cheret
CBCarmen Birchmeier
Carmen Birchmeier
Cholesterol is a major constituent of myelin membranes, which insulate axons and allow saltatory conduction. Therefore, Schwann cells, the myelinating glia of the peripheral nervous system, need to produce large amounts of cholesterol. Here, we define a crucial role of the transcription factor Maf in myelination and cholesterol biosynthesis and show that Maf acts downstream from Neuregulin1 (Nrg1). Maf expression is induced when Schwann cells begin myelination. Genetic ablation of Maf resulted in hypomyelination that resembled mice with defective Nrg1 signaling. Importantly, loss of Maf or Nrg1 signaling resulted in a down-regulation of the cholesterol synthesis program, and Maf directly binds to enhancers of cholesterol synthesis genes. Furthermore, we identified the molecular mechanisms by which Nrg1 signaling regulates Maf levels. Transcription of Maf depends on calmodulin-dependent kinases downstream from Nrg1, whereas Nrg1–MAPK signaling stabilizes Maf protein. Our results delineate a novel signaling cascade regulating cholesterol synthesis in myelinating Schwann cells.